Effective therapeutic design requires optimizing potency, toxicity, availability, and dosage schemes for treatment. Delivery of effective therapies that are able to transport across restrictive endothelial barriers (e.g. blood-brain barrier and HEV-lymph node barrier) remains a central challenge to the treatment of several diseases and cancers.  Additionally, gaining access to the lymph node paracortex can unlock improved vaccines and new therapies for autoimmune disorders.  We are working on drug delivery strategies for enhanced therapeutic delivery to the lymph node and brain.  These projects are in tight collaboration with the Zurakowski and Kwee Laboratories.